NCT06762925View on ClinicalTrials.gov

Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment

Not yet recruitingOBSERVATIONAL
Enrollment

450

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Bladder CancerProstate CancerKidney Cancer
Interventions
OTHER

No Interventions

No Interventions

All Listed Sponsors
lead

Xijing Hospital

OTHER